inositol 🐶 Veterinary Use | Indications/Contra | FAERs-F | FAERs-M | Orange Bk | PK/Tox | Related Drugs | BioActivity |

Stem definitionDrug idCAS RN
1444 87-89-8

Description:

MoleculeDescription

Molfile Inchi Smiles

Synonyms:

  • inositol
  • myo-Inositol
  • cyclohexanehexol
  • cyclohexitol
  • inosital
  • inositene
  • inositina
  • mesoinositol
  • myoinosite
  • myoinositol
An isomer of glucose that has traditionally been considered to be a B vitamin although it has an uncertain status as a vitamin and a deficiency syndrome has not been identified in man. (From Martindale, The Extra Pharmacopoeia, 30th ed, p1379) Inositol phospholipids are important in signal transduction.
  • Molecular weight: 180.16
  • Formula: C6H12O6
  • CLOGP: -0.12
  • LIPINSKI: 1
  • HAC: 6
  • HDO: 6
  • TPSA: 121.38
  • ALOGS: 0.43
  • ROTB: 0

Drug dosage:

None

ADMET properties:

None

Predicted pharmacokinetic/toxicological properties (PK-AZ):

PropertyDescriptionValueUnitConfidenceSimilarity
kinase-safety-class ACVR2A,ACVR2B,AURKA,AXL,BRAF,BTK,CAMK2B,CAMK2D,CDK4,CDK5,CDK9,DDR1,DYRK1B,EIF2AK3,ERBB2,FLT3,GRK2,ITK,MAP2K6,MAP3K21,MAPK10,MAPK7,NTRK2,PDK2,PDK4,PIK3CD,PRKCD,PRKDC,SIK2,SIK3,STK33,SYK,TEK 33
kinase-selectivity-class ACVRL1,AURKB,AXL,BMX,CDK1,CDK16,CDK2,CDK3,CDK4,CDK6,CDK7,CDK8,CDK9,CHUK,DYRK1A,EPHB4,IGF1R,INSR,IRAK1,IRAK3,IRAK4,MAP2K6,MAP3K14,MAP3K21,PDK1,PIK3CB,PIK3CD,PRKDC,TEK,TGFBR1,ZAP70 31
pfas-class PFAS structural alert (1 = True, 0 = False) 0

Approvals:

DateAgencyCompanyOrphan
None FDA

FDA Adverse Event Reporting System (Female)

MedDRA adverse event termLikelihood ratioLikelihood ratio thresholdPatients taking drug having adverse eventPatients taking drug not having adverse eventPatients not taking drug having adverse eventPatients not taking drug not having adverse event
Lip dry 74.84 32.79 53 4679 100902 90522813
Back disorder 67.85 32.79 31 4701 25600 90598115
C-reactive protein abnormal 65.96 32.79 54 4678 127375 90496340
Incorrect route of product administration 55.59 32.79 34 4698 50592 90573123
Dislocation of vertebra 54.94 32.79 35 4697 55933 90567782
Adjustment disorder with depressed mood 54.49 32.79 35 4697 56718 90566997
Injury 51.03 32.79 57 4675 197292 90426423
Breast cancer stage II 50.07 32.79 28 4704 35306 90588409
Rheumatoid factor positive 48.59 32.79 52 4680 171598 90452117
Oedema 43.67 32.79 53 4679 200242 90423473
Musculoskeletal pain 40.09 32.79 47 4685 171204 90452511
Prescribed underdose 37.12 32.79 31 4701 74988 90548727
Amnesia 36.33 32.79 36 4696 108469 90515246
Delirium 35.64 32.79 35 4697 104324 90519391
Anti-cyclic citrullinated peptide antibody positive 35.29 32.79 52 4680 236381 90387334
Joint range of motion decreased 34.72 32.79 39 4693 135604 90488111
Peripheral venous disease 34.11 32.79 31 4701 83890 90539825
Prescribed overdose 33.82 32.79 33 4699 97592 90526123
Fluid retention 32.82 32.79 31 4701 88060 90535655

FDA Adverse Event Reporting System (Male)

None

FDA Adverse Event Reporting System (Geriatric)

MedDRA adverse event termLikelihood ratioLikelihood ratio thresholdPatients taking drug having adverse eventPatients taking drug not having adverse eventPatients not taking drug having adverse eventPatients not taking drug not having adverse event
Lip dry 85.84 46.63 56 5329 100027 110483887
Back disorder 79.42 46.63 32 5353 20890 110563024
Needle fatigue 78.65 46.63 17 5368 1247 110582667
Gait spastic 75.21 46.63 17 5368 1532 110582382
C-reactive protein abnormal 72.76 46.63 56 5329 129639 110454275
Relapsing-remitting multiple sclerosis 70.20 46.63 17 5368 2065 110581849
Dislocation of vertebra 68.04 46.63 36 5349 43685 110540229
Adjustment disorder with depressed mood 67.92 46.63 36 5349 43847 110540067
Rheumatoid factor positive 67.70 46.63 54 5331 131586 110452328
Injury 65.21 46.63 60 5325 177205 110406709
Breast cancer stage II 58.65 46.63 28 5357 27347 110556567
Monoparesis 57.02 46.63 17 5368 4536 110579378
Hypertonic bladder 54.47 46.63 17 5368 5285 110578629
Anti-cyclic citrullinated peptide antibody positive 52.64 46.63 54 5331 181930 110401984
Incorrect route of product administration 50.43 46.63 34 5351 64027 110519887
Oedema 49.65 46.63 56 5329 209920 110373994
Discomfort 48.63 46.63 56 5329 214651 110369263

FDA Adverse Event Reporting System (Pediatric)

None

Pharmacologic Action:

SourceCodeDescription
ATC A11HA07 ALIMENTARY TRACT AND METABOLISM
VITAMINS
OTHER PLAIN VITAMIN PREPARATIONS
Other plain vitamin preparations
MeSH PA D014803 Vitamin B Complex
MeSH PA D014815 Vitamins
MeSH PA D018977 Micronutrients
CHEBI has role CHEBI:23366 compatible osmolytes
CHEBI has role CHEBI:33284 nutrient
CHEBI has role CHEBI:64763 EC 3.1.4.11 (phosphoinositide phospholipase C) inhibitor
CHEBI has role CHEBI:75771 mouse metabolite
CHEBI has role CHEBI:75772 <em>Saccharomyces cerevisiae </em> metabolite
CHEBI has role CHEBI:76971 <em>Escherichia coli</em> metabolite
CHEBI has role CHEBI:77746 human metabolite
CHEBI has role CHEBI:83056 <em>Daphnia magna</em> metabolite

Related Drugs by ATC class:

A11HA Other plain vitamin preparations 10 drugs
biotincalcium pantothenatedexpanthenolnicotinamidepantethinepyridoxal phosphatepyridoxineriboflavintocofersolanVitamin E

Drug Use | Suggest Off label Use Form| |View source of the data|

DiseaseRelationSNOMED_IDDOID
Hypercholesterolemia indication 13644009
Hypoalphalipoproteinemia indication 190785000
Mixed hyperlipidemia indication 267434003
Hypertriglyceridemia indication 302870006
Pellagra indication 418186002 DOID:8457
Niacin deficiency indication 418279001
Slow Progression of Coronary Artery Disease indication
Myocardial Reinfarction Prevention indication
Hyperlipidemia off-label use 55822004 DOID:1168
Hypophosphatemia contraindication 4996001
Alcoholism contraindication 7200002
Peptic ulcer contraindication 13200003 DOID:750
Myocardial infarction contraindication 22298006 DOID:5844
Acute cerebrovascular insufficiency contraindication 29322000
Low blood pressure contraindication 45007003
Blood coagulation disorder contraindication 64779008 DOID:1247
Diabetes mellitus contraindication 73211009 DOID:9351
Hyperglycemia contraindication 80394007 DOID:4195
Gout contraindication 90560007 DOID:13189
Liver function tests abnormal contraindication 166603001
Cerebrovascular accident contraindication 230690007
Arterial hemorrhage contraindication 234003006
Disease of liver contraindication 235856003 DOID:409
Pregnancy, function contraindication 289908002
Thrombocytopenic disorder contraindication 302215000 DOID:1588
Acute coronary syndrome contraindication 394659003
Breastfeeding (mother) contraindication 413712001
Disorder of coronary artery contraindication 414024009
Cerebral infarction contraindication 432504007 DOID:3526




🐶 Veterinary Drug Use

None

🐶 Veterinary products

None

Acid dissociation constants calculated using MoKa v3.0.0

Dissociation levelDissociation constantType (acidic/basic)
pKa1 13.21 acidic
pKa2 13.31 acidic
pKa3 13.71 acidic

Orange Book patent data (new drug applications)

None

Orange Book exclusivity data (new drug applications)

None

Bioactivity Summary:

None

External reference:

IDSource
4017688 VUID
N0000146062 NUI
D08079 KEGG_DRUG
4017688 VANDF
C0021547 UMLSCUI
CHEBI:17268 CHEBI
INS PDB_CHEM_ID
CHEMBL1222251 ChEMBL_ID
DB13178 DRUGBANK_ID
D007294 MESH_DESCRIPTOR_UI
892 PUBCHEM_CID
10437 INN_ID
4L6452S749 UNII
5833 RXNORM
4879 MMSL
5751 MMSL
d00496 MMSL
002057 NDDF
108960004 SNOMEDCT_US
72164009 SNOMEDCT_US

Pharmaceutical products:

ProductCategoryIngredientsNDCFormQuantityRouteMarketingLabel
Lipovite HUMAN PRESCRIPTION DRUG LABEL 13 70104-128 INJECTION 1 mg INTRAMUSCULAR unapproved drug other 1 sections
MIC B12 HUMAN PRESCRIPTION DRUG LABEL 4 70104-806 INJECTION 1 mg INTRAMUSCULAR unapproved drug other 1 sections
NEONATAL PLUS VITAMIN HUMAN PRESCRIPTION DRUG LABEL 17 70898-115 TABLET 5 mg ORAL unapproved drug other 9 sections
One Natal Rx HUMAN PRESCRIPTION DRUG LABEL 17 82568-0141 TABLET 5 mg ORAL unapproved drug other 4 sections
Deep Repair DARK SPOT HUMAN OTC DRUG LABEL 5 84867-001 CREAM 1000 mg CUTANEOUS OTC Monograph Drug 10 sections
HANYWIL Deep Repair DARK SPOT HUMAN OTC DRUG LABEL 5 84867-002 CREAM 1000 mg CUTANEOUS OTC Monograph Drug 11 sections
HANYWIL-DARK SPOT HUMAN OTC DRUG LABEL 5 84867-003 CREAM 1000 mg CUTANEOUS OTC Monograph Drug 11 sections
HANYWIL DARK SPOT HUMAN OTC DRUG LABEL 5 84867-004 SOLUTION, GEL FORMING / DROPS 1500 mg CUTANEOUS OTC Monograph Drug 11 sections